Title: A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

EGFR exon 20 insertion (EGFR ex20ins) mutations comprise about 4-12% [1 –4] of EGFR mutations, which is the third most common category of mutations detected in NSCLC. More than 60 types of EGFR exon 20 insertion mutations have been reported till date [5]. In-frame insertions at exon 20 push the C-helix into its inward position and promote the active conformation of EG FR, which induce ligand-independent activation of EGFR [2]. In clear contrast to common EGFR mutations such as the point mutation in exon 21 L858R and in-frame deletions in exon 19 of EGFR, EGFR ex20ins mutations are known to be resistant to clinically available first and second generation EGFR tyro sine kinase inhibitors (EGFR-TKIs).

Source: Lung Cancer - October 16, 2021 Category: Cancer & Oncology Authors: Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katuyuki Kiura, Yuta Takashima, Seiji Yano, Junji Koyama, Takahi Source Type: research